We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in CinCor Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 102 → 0 (-102)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $461M → $0 (-$461M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 102

Holders
–
Holders Change
-102
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
102
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
-$74.6M
2
5VM
5AM Venture Management
California
-$60.7M
3
GA
General Atlantic
New York
-$51.7M
4
PA
Perceptive Advisors
New York
-$31.7M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$24.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
– -$2.43M -197,896 Closed
CS
27
Candriam SCA
Luxembourg
– -$2.15M -175,000 Closed
Charles Schwab
28
Charles Schwab
California
– -$1.91M -155,534 Closed
UBS Group
29
UBS Group
Switzerland
– -$1.7M -138,614 Closed
Point72 Asset Management
30
Point72 Asset Management
Connecticut
– -$1.44M -116,800 Closed
Two Sigma Investments
31
Two Sigma Investments
New York
– -$1.42M -115,864 Closed
CM
32
Caption Management
Oklahoma
– -$1.34M -109,000 Closed
N
33
Nuveen
North Carolina
– -$1.05M -85,520 Closed
Fidelity Investments
34
Fidelity Investments
Massachusetts
– -$1M -81,740 Closed
Goldman Sachs
35
Goldman Sachs
New York
– -$976K -79,450 Closed
Voloridge Investment Management
36
Voloridge Investment Management
Florida
– -$956K -77,789 Closed
Bank of New York Mellon
37
Bank of New York Mellon
New York
– -$929K -75,622 Closed
WP
38
Woodline Partners
California
– -$907K -73,800 Closed
AA
39
AlphaCentric Advisors
Puerto Rico
– -$860K -70,000 Closed
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$823K -68,621 Closed
CCMU
41
Cheyne Capital Management (UK)
United Kingdom
– -$830K -67,557 Closed
TD Asset Management
42
TD Asset Management
Ontario, Canada
– -$611K -49,730 Closed
DCM
43
DAFNA Capital Management
California
– -$590K -48,000 Closed
AI
44
Atom Investors
Texas
– -$583K -47,401 Closed
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
– -$554K -45,094 Closed
Swiss National Bank
46
Swiss National Bank
Switzerland
– -$494K -40,200 Closed
Russell Investments Group
47
Russell Investments Group
United Kingdom
– -$492K -40,062 Closed
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
– -$447K -36,335 Closed
CSS
49
Cubist Systematic Strategies
Connecticut
– -$443K -36,019 Closed
PI
50
Putnam Investments
Massachusetts
– -$439K -35,728 Closed
1
2
3 4

CINC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q1 2023, worth a combined $0 — down 100% from $461M a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of CINC and 0 opened new positions — a net loss of 102 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sofinnova Investments, exiting entirely with an estimated $74.6M sold.

  • 0 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q1 2023, down from 102 in Q4 2022.
  • Funds reported $0 of CinCor Pharma, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new CinCor Pharma, Inc. Common Stock positions in Q1 2023 and 102 closed out, a net change of -102 holders.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q1 2023 was Sofinnova Investments, an estimated $74.6M sold.

Based on aggregated 13F filings for Q1 2023.